The ability of neuropeptide Y to mediate responses in the murine cutaneous microvasculature: An analysis of the contribution of Y 1 and Y 2 receptors

British Journal of Pharmacology

Volumn 140, Issue 2, 2003, Pages 422-430

  Chu, Duc Quyen ^a   Cox, Helen M ^a   Costa, Soraia K P ^a   Herzog, Herbert ^b   Brain, Susan D ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Blood flow; Microvascular; Mouse; Neuropeptide Y; Oedema formation; Skin

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; N2 DIPHENYLACETYL N (4 UREIDOMETHYLBENZYL)ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR AGONIST; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; PEPTIDE YY; RECEPTOR ANTIBODY; TECHNETIUM 99M;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VOLUME; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG INJECTION VOLUME; EDEMA; FEMALE; KNOCKOUT MOUSE; LOW DRUG DOSE; MALE; MEASUREMENT; MICROVASCULATURE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; SKIN BLOOD FLOW; VASODILATATION;

ANIMALS; ARGININE; CAPILLARY PERMEABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; FEMALE; GENOTYPE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROPEPTIDE Y; NEUTROPHILS; PEPTIDE YY; RECEPTORS, NEUROPEPTIDE Y; REGIONAL BLOOD FLOW; SKIN;

EID: 0141923020     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705452     Document Type: Article

References (59)

1. BATTERHAM, R.L., COWLEY, M.A., SMALL, C.J., HERZOG, H., COHEN, M.A., DAKIN, C.L., WREN, A.M., BRYNES, A.E., LOW, M.J., GHATEI, M.A., CONE, R.D. & BLOOM, S.R. (2002). Gut hormone PYY(3-36) physiologically inhibits food intake. Nature, 418, 650-654.
2. BÖTTCHER, G., SJÖLUND, K., EKBLAD, E., HÅKANSON, R.. SCHWARTZ, T.W. & SUNDLER, F. (1984). Coexistence of peptide YY and glicentin immunoreactivity in endocrine cells of the gut. Regul. Pept., 8, 261-266.
3. CAO, T., GERARD, N.P. & BRAIN, S.D. (1999). Use of NK(1) knockout mice to analyze substance P-induced edema formation. Am. J. Physiol., 277, R476-R481.
4. CAO, T., PINTER, E., AL-RASHED, S., GERARD, N., HOULT, J.R. & BRAIN, S.D. (2000). Neurokinin-1 receptor agonists are involved in mediating neutrophil accumulation in the inflamed, but not normal, cutaneous microvasculature: an in vivo study using neurokinin-1 receptor knockout mice. J. Immunol., 164, 5424-5429.
5. CHU, D.Q., LEGON, S., SMITH, D.M., COSTA, S.K., CUTTITTA, F. & BRAIN, S.D. (2001). The calcitonin gene-related peptide (CGRP) antagonist CGRP(8-37) blocks vasodilatation in inflamed rat skin: involvement of adrenomedullin in addition to CGRP. Neurosci. Lett., 310, 169-172.
6. COX, H.M., POLLOCK, E.L., TOUGH, I.R. & HERZOG, H. (2001). Multiple Y receptors mediate pancreatic polypeptide responses in mouse colon mucosa. Peptides, 22, 445-452.
7. 4 receptors mediate Y agonist responses in isolated human colon mucosa. Br. J. Pharmacol., 135, 1505-1512.
8. DOODS, H., GAIDA, W., WIELAND, H.A., DOLLINGER, H., SCHNORRENBERG, G., ESSER, F., ENGEL, W., EBERLEIN, W. & RUDOLF. K. (1999). BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist. Eur. J. Pharmacol., 384, R3-R5.
9. DUMONT, Y., CADIEUX, A., DOODS, H., PHENG, L.H., ABOUNADER, R., HAMEL, E., JACQUES, D., REGOLI, D. & QUIRION, R. (2000). BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist. Br. J. Pharmacol., 129, 1075-1088.
10. EDVINSSON, L., COPELAND, J.R., EMSON, P.C., MCCULLOCH, J. & UDDMAN, R. (1987). Nerve fibers containing neuropeptide Y in the cerebrovascular bed: immunocytochemistry, radioimmunoassay, and vasomotor effects. J. Cereb. Blood Flow Metab., 7, 45-57.
11. EDVINSSON, L., EKBLAD, E., HAKÅNSON. R. & WAHLESTEDT, C. (1984b). Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels. Br. J. Pharmacol., 83, 519-525.
12. EDVINSSON, L., EMSON, P., MCCULLOCH, J., TATEMOTO, K. & UDDMAN, R. (1984a). Neuropeptide Y: immunocytochemical localization to and effect upon feline pial arteries and veins in vitro and in situ. Acta. Physiol. Scand., 122, 155-163.
13. EKBLAD, E., EDVINSSON, L., WAHLESTEDT, C., UDDMAN, R., HÅKANSON, R. & SUNDLER, F. (1984). Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul. Pept., 8, 225-235.
14. EKSTRAND, A.J., CAO, R., BJORNDAHL, M., NYSTROM, S., JONSSON-RYLANDER, A.C., HASSANI, H., HALLBERG, B., NORDLANDER, M. & CAO, Y. (2003). Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc. Natl. Acad. Sci. U.S.A., 100, 6033-6038.
15. 34 neuropeptide Y: a specific Y1 receptor agonist. Proc. Natl. Acad. Sci. U.S.A., 87, 182-186.
16. GERALD, C., WALKER, M.W., VAYSSE, P.J., HE, C., BRANCHEK, T.A. & WEINSHANK, R.L. (1995). Expression cloning and pharmacological characterization of a human hippocampal neuropeptide Y/peptide YY Y2 receptor subtype. J. Biol. Chem., 270, 26758-26761.
17. GRANDT, D., SCHIMICZEK, M., BEGLINGER, C.H., LAYER, P., GOEBELL, H., EYSSELEIN, V.E. & REEVE, J.R. (1994). Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY1-36 and PYY3-36. Regul. Pept., 51, 151-159.
18. GRANT, A.D., AKHTAR, R., GERARD, N.P. & BRAIN, S.D. (2002). Neurokinin B induces oedema formation in mouse lung via tachykinin receptor-independent mechanisms. J. Physiol., 543, 1007-1014.
19. GRUNDEMAR, L. & HÅKANSON, R. (1990). Effects of various neuropeptide Y/peptide YY fragments on electrically evoked contractions of the rat vas deferens. Br. J. Pharmacol., 100, 190-192.
20. HASHIM, M.A. & TADEPALLI, A.S. (1995). Cutaneous vasomotor effects of neuropeptide Y. Neuropeptides, 29, 263-271.
21. HERZOG, H., HORT, Y., SHINE. J. & SELBIE, L. (1992). Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc. Natl. Acad. Sci. U.S.A., 9, 5794-5798.
22. HYLAND, N.P., SJOBERG, F., TOUGH, I.R., HERZOG, H. & COX, H.M. (2003). Functional consequences of neuropeptide Y Y2 receptor knockout and Y2 antagonism in mouse and human colonic tissues. Br. J. Pharmacol., 139, 863-871.
23. KASHIBA, H., NOGUCHI, K., UEDA, Y. & SENBA, E. (1994). Neuropeptide Y and galanin are coexpressed in rat large type A sensory neurons after peripheral transection. Peptides, 15, 411-416.
24. KITLINSKA, J., LEE, E.W., MOVAFAGH, S., PONS, J. & ZUKOWSKA, Z. (2002). Neuropeptide Y-induced angiogenesis in aging. Peptides, 23, 71-77.
25. LAMBERT, R.W., CAMPTON, K., DING, W., OZAWA, H. & GRANSTEIN, R.D. (2002). Langerhans cell expression of neuropeptide Y and peptide YY. Neuropeptides, 36, 246-251.
26. LEE, E.W., GRANT, D.S., MOVAFAGH, S. & ZUKOWSKA, Z. (2003). Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor knockout mice. Peptides, 24, 99-106.
27. LUNDBERG, J.M., MARTINSSON, A., HEMSEN, A., THEODORSSON-NORHEIM, E., SVEDENHAG, J., EKBLOM, B. & HJEMDAHL, P. (1985). Co-release of neuropeptide Y and catecholamines during physical exercise in man. Biochem. Biophys. Res. Commun., 133, 30-36.
28. LUNDBERG, J.M. & MODIN, A. (1995). Inhibition of sympathetic vasoconstriction in pigs in vivo by the neuropeptide Y-Y1 receptor antagonist BIBP 3226. Br. J. Pharmacol, 116, 2971-2982.
29. LUNDBERG, J.M. & TATEMOTO, K. (1982). Pancreatic polypeptide family (APP, BPP, NPY and PYY) in relation to sympathetic vasoconstriction resistant to alpha-adrenoceptor blockade. Acta Physiol. Scand., 116, 393-402.
30. LUNDBERG, J.M., TERENIUS, L., HÖKFELT, T., MARTLING, C.R., TATEMOTO, K., MUTT, V., POLAK, J., BLOOM, S. & GOLDSTEIN, M. (1982). Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol. Scand., 116, 477-480.
31. MALMSTRÖM, R.E. (2001). Vascular pharmacology of BIIE0246, the first selective non-peptide neuropeptide Y Y(2) receptor antagonist, in vivo. Br. J. Pharmacol., 133, 1073-1080.
32. MALMSTRÖM, R.E. (2002). Pharmacology of neuropeptide Y receptor antagonists. Focus on cardiovascular functions. Eur. J. Pharmacol., 447, 11-30.
33. MALMSTRÖM, R.E., HOKFELT, T., BJÖRKMAN, J.A., NIHLEN, C., BYSTROM, M., EKSTRAND, A.J. & LUNDBERG, J.M. (1998). Characterization and molecular cloning of vascular neuropeptide Y receptor subtypes in pig and dog. Regul. Pept., 75-76, 55-70.
34. 1 receptor antagonist SR 120107A on sympathetic vascular control in pigs in vivo. Naunyn Schmiedeberg's Arch. Pharmacol., 354, 633-642.
35. 2 receptor antagonist BIIE0246 on sympathetic transmitter release in the pig in vivo. Naunyn Schmiedeberg's Arch. Pharmacol., 365, 106-111.
36. MARSH, D.J., HOLLOPETER, G., KAFER, K.E. & PALMITER, R.D. (1998). Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat. Med., 6, 718-721.
37. MCAULEY, M.A. & WESTFALL, T.C. (1992). Possible location and function of neuropeptide Y receptor subtypes in the rat mesenteric arterial bed. J. Pharmacol. Exp. Ther., 261, 863-868.
38. MENTLEIN, R., DAHMS, P., GRANDT, D. & KRUGER, R. (1993). Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul. Pept., 49, 133-144.
39. MICHEL, M.C., BECK-SICKINGER, A., COX, H., DOODS, H.N., HERZOG, H., LARHAMMAR, D., QUIRION, R., SCHWARTZ, T. & WESTFALL, T. (1998). XVI International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev., 50, 143-150.
40. MODIN, A., PERNOW, J. & LUNDBERG, J.M. (1991). Evidence for two neuropeptide Y receptors mediating vasoconstriction. Eur. J. Pharmacol., 203, 165-171.
41. MORONEY, M.A., ALCARAZ, M.J., FORDER, R.A., CAREY, F. & HOULT, J.R. (1988). Selectivity of neutrophil 5-lipoxygenase and cyclo-oxygenase inhibition by an anti-inflammatory flavonoid glycoside and related aglycone flavonoids. J. Pharm. Pharmacol., 40, 787-792.
42. MORRIS, J.L. (1994). Selective constriction of small cutaneous arteries by NPY matches distribution of NPY in sympathetic axons. Regul. Pept.,49, 225-236.
43. MORRIS, J.L. (1999). Cotransmission from sympathetic vasoconstrictor neurons to small cutaneous arteries in vivo. Am. J. Physiol., 277, H58-H64.
44. NAVEILHAN, P., HASSANI, H., LUCAS, G., BLAKEMAN, K.H., HAO, J.X., XU, X.J., WIESENFELD-HALLIN, Z., THOREN, P. & ERNFORS, P. (2001). Reduced antinociception and plasma extravasation in mice lacking a neuropeptide Y receptor. Nature, 409, 513-517.
45. 1 receptors. J. Cardiovasc. Pharmacol., 28, 764-768.
46. PINTER, E., HELVES, Z., PETHO, G. & SZOLCSANYI, J. (1997). Noradrenergic and peptidergic sympathetic regulation of cutaneous microcirculation in the rat. Eur. J. Pharmacol., 325, 57-64.
47. POTTER, E.K. (1985). Prolonged non-adrenergic inhibition of cardiac vagal action following sympathetic stimulation: neuromodulation by neuropeptide Y? Neurosci Lett., 54, 117-121.
48. SAINSBURY, A., SCHWARZER, C., COUZENS, M., FETISSOV, S., FURTINGER, S., JENKINS, A., COX, H.M., SPERK, G., HOKFELT, T. & HERZOG, H. (2002). Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knock out mice. Proc. Natl. Acad. Sci. U.S.A., 99, 8938-8943.
49. SCHIERWAGEN, C., BYLUND-FELLENIUS, A.C. & LUNDBERG, C. (1990). Improved method for quantification of tissue PMN accumulation measured by myeloperoxidase activity. J. Pharmacol. Methods, 23, 179-186.
50. SHEN, G.H., GRUNDEMAR, L., ZUKOWSKA-GROJEC, Z., HAKÅNSON, R. & WAHLESTEDT, C. (1991). C-terminal neuropeptide Y fragments are mast cell-dependent vasodepressor agents. Eur. J. Pharmacol., 204, 249-256.
51. SHIN, L.H., DOVGAN, P.S., NYPAVER, T.J., CARRETERO, O.A. & BEIERWALTES, W.H. (2000). Role of neuropeptide Y in the development of two-kidney, one-clip renovascular hypertension in the rat. J. Vasc. Surg., 32, 1015-1021.
52. TATEMOTO, K., CARLQUIST, M. & MUTT, V. (1982). Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature, 296, 659-660.
53. TESSEL, R.E., MILLER, D.W., MISSE, G.A., DONGM, X. & DOUGHTY, M.B. (1993). Characterization of vascular postsynaptic NPY receptor function and regulation and differential sensitivity of Y1 and Y2 receptor function to changes in extracellular calcium availability and prior in vitro peptide exposure. Neuropeptides, 25, 289-298.
54. UDDMAN, R., MOLLER, S., NILSSON, T., NYSTROM. S., EKSTRAND, J. & EDVINSSON, L. (2002). Neuropeptide Y Y1 and neuropeptide Y Y2 receptors in human cardiovascular tissues. Peptides, 23, 927-934.
55. VOULDOUKIS, I., SHAI, Y., NICOLAS, P. & MOR, A. (1996). Broad spectrum antibiotic activity of the skin-PYY. FEBS Lett., 380, 237-240.
56. WALLENGREN, J. (1997). Vasoactive peptides in the skin. J. Investig. Dermatol. Symp. Proc., 2, 49-55.
57. WEIHE, E. & HARTSCHUH, W. (1988). Multiple peptides in cutaneous nerves: regulators under physiological conditions and a pathogenetic role in skin disease? Semin. Dermatol., 7, 284-300.
58. WIELAND, H.A., ENGEL, W., EBERLEIN, W., RUDOLF, K. & DOODS, H.N. (1998). Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br. J. Pharmacol., 125, 549-555.
59. ZUKOWSKA-GROJEC, Z., KARWATOWSKA-PROKOPCZUK, E., ROSE, W., RONE, J., MOVAFAGH, S., JI, H., YEH, Y., CHEN, W.T., KLEINMAN, H.K., GROUZMANN, E. & GRANT, D.S. (1998). Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ. Res., 83, 187-195.